Phylogica Ltd (ASX: PYC, XETRA: PH7) reported that it has has signed its fourth partnership with a major pharmaceutical company. Today, we have announced a Collaboration and Option agreement with Janssen Biotech, Inc., which is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. This partnership has the broadest scope of any of our collaborations to-date and could lead to the development of multiple Phylomer-based products.  

With the addition of Janssen, Phylogica has signed  deals with four of the top five global pharmaceutical companies; and has made demonstrable progress over the last 12 months with all its collaborative discovery programmes. Our collaboration with MedImmune, the biologics arm of AstraZeneca, has recently advanced to the final stage of the research plan. Furthermore, in December 2011, we reported the successful completion of the fist stage of our collaboration with Pfizer. These milestones followed our announcement earlier in 2011 that we successfully achieved the objectives in our research alliance with Roche

Source: PYC